DARPA launched The Pandemic Prevention Platform (P3) program in 2017 to develop an integrated system that could stop a viral pandemic by “delivering medical countermeasures within 60 days of identifying a new pathogen” – its primary focus was on using mRNA technology to deliver instructions for the body to produce its own monoclonal antibodies. (01) (02) (03)
P3 was the critical research and development engine that made Warp Speed possible.
1.) It funded the early-research for the players, and it created the playbook. The entire P3 program was designed around answering one question: How do we go from a unknown virus to a treatment in 60 days? The simulations and the tabletop exercises were essentially dress rehearsals for COVID-19. When the the CONvid narrative appeared, the people running P3 didn’t have to figure out what to do, they followed their plan.
2.) P3 Built the “Rapid Response” Infrastructure. P3 built a distributed, rapid-response network.
Dr. Amy Jenkins, the P3 program manager, noted that before the program, the prevailing wisdom was that antibody discovery took years. P3 forced the science to move faster.
3.) Once you add Operation “Warp Speed”, Emergency Powers, and censorship into the mix, you’re able to rush things to approval, make opposition invisible or smear them as ‘terrorists’, mass manufacture and distribute, and print money – lots and lots of money.
- Everything was tested against the PCR test – a computer code – something that could be found in anyone under the right conditions (I really would love to spend time to explain this and address every argument that’s thrown at it, it’s so important, yet so damn hard – lengthy – to explain, it’s “on the list” for “one day”)
- Institutions lied, or were so incompetent they didn’t question the “test” or never considered they could be lying
- The media believed the institutions, and amplified the lie
- The online media provided real-time censorship and fake AI chat bots – banning and smearing anyone who went against the narrative
- Scientists believed the test and became unknowing accomplices
- Millions of people made life-altering decisions based on something that wasn’t real in the way they thought
- People died from taking the wrong pharmaceuticals
- People died alone and scared, no final comfort from their loved ones
- People injected themselves with an untested “serum” that was created with the PCR test as it’s measuring tool – to work, to visit grandma, to hold their child’s hand in hospitals, to travel, to save their marriage, or because they thought it was actually saving lives
- People split with family, life-long friends, and their jobs
- The whole world was changed, the whole world’s laws were changed, society was changed, everything was changed
- The rich got richer, the middle class joined the poor
Funding
Duke University Human Vaccine Institute
Duke University’s Human Vaccine Institute received $12.8 million in October 2017 for a 30-month grant to lead a consortium that included partners such as the University of Pennsylvania, the University of Texas at Austin, and Synthetic Genomics Vaccines Inc. (04)
For the P3 program, the Duke Vaccine Institute research group had been studying a variety of model organisms in 2018 and 2019, including a respiratory virus, specifically influenza. (05)
“We had gotten to the proof-of concept point in November/December of 2019, and then wham! We had the potential to help with COVID-19 and we started racing,” ~ Thomas Denny, chief operating officer of the Duke Human Vaccine Institute
They received an additional $7.6 million from DARPA in 2020 to manufacture and conduct Phase 1 human trials of a COVID-19 monoclonal antibody using RNA delivery. (06)
They used the $20.4 million DARPA funding to fund multiple institutions:
- “Identifying the optimal lipid nanoparticle carrier to deliver the mRNA” (University of Pennsylvania) (07)
- “Expertise in antibody engineering and evolution” (University of Texas – who also got an extra $51 million in 2020 from the NIAID (Fauci) for the “first year” to create longer-lasting influenza vaccines) (08)
- Contributing synthetic biology technologies for rapid countermeasure delivery (Synthetic Genomics Vaccines Inc) (09)
And they created a platform that is supposed to isolate antibodies using blood samples from “recovered COVID-19 patients”, identify B cells, clone their sequences, and generate potential mRNA sequences to make SARS-CoV-2 antibodies in a few weeks. They apparently generated 2,500 potential mRNA sequences from patients. (10) (11) (12)
But if the patient never had a virus to begin with, then what are they producing? An antibody from “someone who was told they had a virus”?
- The PCR test (a computer-interpreted code with arbitrary Ct cutoffs) is the only thing that officially defined someone as a “COVID-19 patient.”
- Researchers then took blood from those “patients” to discover antibodies.
- Those antibodies were then used to create therapeutics and validate vaccines.
- The success of those therapeutics was measured by… the same PCR test.
- and apparently they use a synthetic spike protein to test it, and then to test against a “live” virus? That’s done with the blood of a patient… who has been diagnosed with COVID-19 by… the same PCR test.
They also used the funding to:
- Manufacture their lead candidate and prepare for a Phase 1 human trial (didn’t get FDA approval, or, if they did, I can’t find it and don’t want to spend all night looking)
- Support their existing cGMP manufacturing facility and biocontainment labs, which are national resources for infectious disease research
AbCellera Biologics Inc.
AbCellera Biologics Inc. was awarded a contract worth up to $30 million in March 2018 for a four-year term to lead a team of experts in virology, antibody discovery, and gene therapy. (13)
“To achieve this ambitious goal, AbCellera and its partners will develop and integrate innovative technologies for viral culture and production, rapid human antibody discovery, protein engineering, and delivery of nucleic acid-encoded antibodies as prophylactic protection against viral infection. AbCellera’s platform development and testing will include the discovery of thousands of human antibodies against a wide array of influenza strains and validation using a variety of other high-priority viral pathogens.”
AbCella’s DARPA-funded platform (P3) directly enabled the discovery of two significant COVID-19 monoclonal antibody therapies in partnership with Eli Lilly: (14)
Bamlanivimab (LY-CoV555): which was used to treat more patients than any other neutralizing antibody, and was the world’s first monoclonal antibody therapy for “COVID-19” to enter human clinical trials. It was created in just 90 days, and received the first FDA EUA for treating CONvid.
Bebtelovimab (LY-CoV1404): a second-generation antibody discovered using the same AbCellera AI-powered platform. Specifically designed to maintain effectiveness against evolving variants, including early Omicron subvariants. (15)
- Revenue: AbCellera generated over USD $300 million in COVID-related revenue in 2021 from these discoveries. (16)
- Government Backing: The success of the DARPA project led to further major investments, including CA $701 million from the Canadian government to build a specialized biotech campus. “It also forged deep government and industry relationships (e.g. the U.S. Dept. of Defense and Eli Lilly) that continue today.” (17)
AstraZeneca
MedImmune (AstraZeneca) – DARPA & BARDA provided the foundational “rapid response” R&D funding to AstraZeneca, and HHS gave them $125 million for the ‘advanced development and manufacturing of a COVID-19 vaccine’. (18)
These researchers couldn’t track down all of AZ’s C19 funding, despite writing a paper on it. (19)
The CDC has given them contracts ranging from $8.5 million to $75.5 million for different flu seasons for “adult and pediatric influenza vaccines”.
They received over $1.3 billion from the US government alone (let alone the rest of the world) for the large-scale trials, manufacturing, and distribution of its COVID-19 medical countermeasures. (20) (21)
Clearly “Pandemic Preparedness” is profitable for AstraZeneca, since in 2024, they announced they were investing 650 million pounds in UK to boost ‘pandemic preparedness’. (22)
VUMC
Vanderbilt University Medical Center (VUMC): In January 2018, DARPA signed a five-year cooperative agreement with VUMC worth up to USD $28 million. (23)
This team specialized in “antibody sprints” to identify neutralizing antibodies against viruses like Zika and COVID-19 within weeks. In June 2020, VUMC and partner AstraZeneca received an additional $23.7 million from DARPA and BARDA specifically to accelerate COVID-19 therapeutic trials. (24)
Major funding sources for the Vanderbilt Vaccine Center (VVC) include DARPA, the Defense Advanced Research Projects Agency of the U.S. Department of Defense (DoD) and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. (25)
The Vanderbilt researchers were preparing to embark on a second outbreak simulation in January, when “on a dime, we shifted from thinking about simulating a bird flu outbreak to doing the real thing with coronavirus”. (26)
So after these millions were given, when “COVID-19” came and it was time to “bring antibody treatments”, they apparently were able to isolate SARS-CoV-2 antibodies (Hmm dubious about that, but that’s beside the point)… they claimed they did and rushed straight to the patent-office (to, you know, save the world), filing 11 patent applications on the same day. “Dibs” on the antibodies; at least on paper. (27)
And last year, a $30 million grant was awarded to Vanderbilt University Medical Center by Advanced Research Projects Agency for Health (ARPA-H) to support the development of Artificial-Intelligence-powered antibody therapies. (28) (29)
Moderna
DARPA awarded $25 million to Moderna in 2013 for ADEPT: Autonomous Diagnostics to Enable Prevention and Therapeutics to help establish its messenger RNA platform, which was critical to the technology later utilized in the P3 program’s goals. (30) (31) (32)
Pfizer
DARPA also awarded Pfizer a $7.7 million contract in 2013 for work directly aligned with the goals of what would later become the Pandemic Prevention Platform (P3) program. (33) (34)
